![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Regeneron’s COVID-19 Antibody Cocktail Wins UK Approval
Regeneron’s COVID-19 Antibody Cocktail Wins UK Approval
![Regeneron logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Regeneron_Logo.png?t=1631745771&width=430)
August 23, 2021
The UK’s Medicines and Healthcare products Regulatory Agency has approved Regeneron’s antibody cocktail Ronapreve (casirivimab/imdevimab) — known as REGEN-COV in the U.S. — for preventing and treating COVID-19.
The conditional marketing authorization was supported by positive results from two phase 3 trials that evaluated the cocktail’s ability to prevent symptomatic infection in high-risk, nonhospitalized patients. The drug has also been shown to retain effectiveness against variants of concern, including the Delta strain.
In the U.S., REGEN-COV received a revised FDA indication approval earlier this month for prevention of COVID-19 infection in individuals 12 years and older who have been exposed to the coronavirus and are at high risk of progressing to severe disease.
Upcoming Events
-
21Oct